Jazz Pharmaceuticals
VC Fund
Palo Alto, United States
Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. Jazz Pharmaceuticals focuses on identifying, developing, and commercializing products for neurology and psychiatry primarily in the United States. Its productsinclude Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Cystadane for the treatment of homocystinuria, an inherited metabolic disease; and Antizol to treat ethylene glycol and methanol poisoning. Its late-stage product candidates comprise Luvox CR, an extended-release formulation of fluvoxamine, a selective serotonin reuptake inhibitor, which is used for the treatment of obsessive-compulsive disorder and social anxiety disorder; and JZP-6, a liquid dosage form of sodium oxybate in Xyrem, for the treatment of fibromyalgia syndrome.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Jazz Pharmaceuticals invests in
Stages Jazz Pharmaceuticals invests in
Countries Jazz Pharmaceuticals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bruce Cozadd
|
|||
Chris Tovey
|
|||
Dennis Engelke
|
|||
Fintan Keegan
|
|||
Iain McGill
|
|||
| See all 12 contacts → | |||
Investment Focus
Industry
- Medical Device 3 (75%)
- Wearables 2 (50%)
- Health Care 2 (50%)
- Nanotechnology 2 (50%)
- Medical 1 (25%)
Stage
- Series A 2 (50%)
- Series B 2 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Bruce Cozadd
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
|
Chris Tovey
Chief Operating Officer
|
Chief Operating Officer | Total investments: 0 | Find email | |
|
Dennis Engelke
Executive Director, Country Manager Switzerland & Austria
|
Executive Director, Country Manager Switzerland & Austria | Total investments: 0 | Find email | |
|
Fintan Keegan
Executive Vice President, Technical Operations
|
Executive Vice President, Technical Operations | Total investments: 0 | Find email | |
|
Iain McGill
Head of EUSA International and SVP, Jazz Pharmaceuticals
|
Head of EUSA International and SVP, Jazz Pharmaceuticals | Total investments: 0 | Find email | |
| See all 12 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life ofpatients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. | $12.5M / Series B / Jul 29, 2021 | ||
| Onera is a spin-off of imec, the world-leading research center for nanoelectronics and digital technology. Onera’s mission is to advance sleep medicine by creating breakthrough diagnostic solutions and services, helping millions of people who struggle with sleep-related ailments, and ultimately improving the health and quality of life for patientsaround the world. Onera is headquartered in California’s Silicon Valley and has R&D offices in the Netherlands. For more information, please visit www.onerahealth.com | $11.5M / Series B / Jul 29, 2021 | ||
| Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life ofpatients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the US. | $9.1M / Series A / Apr 24, 2019 | ||
| Our expertise is drug development. Whether we are developing a reformulated product, a new chemical entity, or a biologic, the team at Arrivo BioVentures has expertise in identifying regulatory strategies to expedite the path to approval and the efficient implementation of the clinical programs themselves. We coordinate with the FDA (and otherregulatory bodies) early and often to gain agreement on the development programs for our products, minimizing surprises and speeding implementation. | $49M / Series A / May 25, 2016 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jazz Pharmaceuticals invest in?
Jazz Pharmaceuticals invests primarily in Medical Device, Wearables and Health Care startups, most often at Series A and Series B stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jazz Pharmaceuticals?
Public channels for Jazz Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Jazz Pharmaceuticals?
The team at Jazz Pharmaceuticals includes Bruce Cozadd (Chief Executive Officer), Chris Tovey (Chief Operating Officer) and Dennis Engelke (Executive Director, Country Manager Switzerland & Austria), among 12 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
